AAP
TRDA icon

Arax Advisory Partners’s Entrada Therapeutics TRDA Stock Holding History

Arax Advisory Partners’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33K Buy
4,478
+3,559
+387% +$34.1K ﹤0.01% 3607
2026
Q1 		$11.6K Buy
919
+1
+0.1% +$11 ﹤0.01% 2363
2025
Q4 		$9.44K Sell
918
-361
-28% -$3.04K ﹤0.01% 2499
2025
Q3 		$7.42K Buy
1,279
+814
+175% +$4.76K ﹤0.01% 2725
2025
Q2 		$3.13K Buy
+465
New +$3.74K ﹤0.01% 2414
2024
Q4 		– Sell
-45
Closed -$720 – 2747
2024
Q3 		$720 Hold
45
– – ﹤0.01% 2337
2024
Q2 		$642 Buy
+45
New +$640 ﹤0.01% 2287

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Arax Advisory Partners's TRDA Position: Q2 2026 in Review

Arax Advisory Partners increased its Entrada Therapeutics (TRDA) stake by 387% in Q2 2026, buying an estimated $34.1K and bringing the position to 4,478 shares worth $33K. The position accounts for ﹤0.01% of the portfolio, ranked #3607.

Arax Advisory Partners first reported a position in TRDA in Q2 2024 and has held it in 7 quarters since. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Arax Advisory Partners held 4,478 shares of Entrada Therapeutics worth $33K as of Q2 2026.
  • Arax Advisory Partners bought 3,559 Entrada Therapeutics shares in Q2 2026, an estimated $34.1K.
  • Entrada Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3607 holding.
  • Arax Advisory Partners first reported a position in Entrada Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.